Corporate Social Responsibility in Innovation: Insights from two Cases of Syngenta's Activities in Genetically Modified Organisms
Publikation: Beiträge in Zeitschriften › Zeitschriftenaufsätze › Forschung › begutachtet
Standard
in: Creativity and Innovation Management, Jahrgang 21, Nr. 2, 06.2012, S. 199-211.
Publikation: Beiträge in Zeitschriften › Zeitschriftenaufsätze › Forschung › begutachtet
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Corporate Social Responsibility in Innovation: Insights from two Cases of Syngenta's Activities in Genetically Modified Organisms
AU - Weisenfeld, Ursula
PY - 2012/6
Y1 - 2012/6
N2 - Corporate social responsibility (CSR) implies that companies have collective responsibility beyond legal requirements. This ‘beyond’ can be described along the ‘triple bottom line’ of sustainability (social, environmental and economic dimensions). Dealing with these dimensions is under discussion in societies and some propose the stakeholder concept as a framework for companies to identify their responsibilities. However, who counts as a key stakeholder and what is a legitimate stake are difficult to determine. This article discusses reasons, possibilities and difficulties of managing responsibility in innovation, taking two cases of genetically modified organisms as examples. It is argued that the stakeholder approach is necessary to provide different perspectives, but is not enough or even completely unsuitable for defining responsibilities. Moral responsibility involves judgement that differs between stakeholders and might vary over time, owing to emerging insights and changing priorities. Therefore, pursuing or abandoning a particular project does not constitute a responsible organization; rather, it is the preparation of decisions, accountability and the resulting pattern of behaviour that renders an organization responsible. The various notions of responsibility set the scene for discussion but do not provide a clear answer to the questions of right or wrong and good or ill intent. Key conclusions are that companies need to organize for responsibility and that responsibility needs to be complemented with accountability.
AB - Corporate social responsibility (CSR) implies that companies have collective responsibility beyond legal requirements. This ‘beyond’ can be described along the ‘triple bottom line’ of sustainability (social, environmental and economic dimensions). Dealing with these dimensions is under discussion in societies and some propose the stakeholder concept as a framework for companies to identify their responsibilities. However, who counts as a key stakeholder and what is a legitimate stake are difficult to determine. This article discusses reasons, possibilities and difficulties of managing responsibility in innovation, taking two cases of genetically modified organisms as examples. It is argued that the stakeholder approach is necessary to provide different perspectives, but is not enough or even completely unsuitable for defining responsibilities. Moral responsibility involves judgement that differs between stakeholders and might vary over time, owing to emerging insights and changing priorities. Therefore, pursuing or abandoning a particular project does not constitute a responsible organization; rather, it is the preparation of decisions, accountability and the resulting pattern of behaviour that renders an organization responsible. The various notions of responsibility set the scene for discussion but do not provide a clear answer to the questions of right or wrong and good or ill intent. Key conclusions are that companies need to organize for responsibility and that responsibility needs to be complemented with accountability.
KW - Management studies
KW - CSR
KW - Corporate Social Responsibility
UR - http://www.scopus.com/inward/record.url?scp=84878022083&partnerID=8YFLogxK
U2 - 10.1111/j.1467-8691.2012.00643.x
DO - 10.1111/j.1467-8691.2012.00643.x
M3 - Journal articles
VL - 21
SP - 199
EP - 211
JO - Creativity and Innovation Management
JF - Creativity and Innovation Management
SN - 0963-1690
IS - 2
ER -